Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Perospirone.

S V Onrust1, K McClellan

  • 1Adis International Limited, Mairangi Bay, Auckland, New Zealand.

CNS Drugs
|July 21, 2001
PubMed
Summary
This summary is machine-generated.

Perospirone, an atypical antipsychotic, effectively treats schizophrenia symptoms, including negative and general symptoms, with a rapid onset of action. It demonstrates a favorable side effect profile, with fewer extrapyramidal symptoms compared to other treatments.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Proton damage in (Y,Lu,Gd)<sub>3</sub>(Al,Ga)<sub>5</sub>O<sub>12</sub>:Ce mixed garnet scintillators.

The Review of scientific instruments·2022
Same author

Brain sex differences and hormone influences: a moving experience?

Journal of neuroendocrinology·2009
Same author

Infliximab: a review of its use in Crohn's disease and rheumatoid arthritis.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Infective keratitis in older patients: a 4 year review, 1998-2002.

The British journal of ophthalmology·2005
Same author

Penetrating keratoplasty in children: visual and graft outcome.

The British journal of ophthalmology·2003
Same author

Corneal endothelial deposits secondary to rifabutin prophylaxis for Mycobacterium avium complex bacteraemia.

The British journal of ophthalmology·2003
Same journal

Impact of Omaveloxolone on Serum Lipids in Patients with Friedreich Ataxia: A 1-Year Real-World Analysis.

CNS drugs·2026
Same journal

Emerging Pharmacological Strategies for Trigeminal Neuralgia.

CNS drugs·2026
Same journal

Psychiatric Symptoms Associated with Corticosteroid Use: A Systematic Review and Meta-analysis.

CNS drugs·2026
Same journal

Anti-CD20 Therapies in Pediatric Acquired Demyelinating Syndromes: Evidence Across MS, AQP4-IgG-Positive NMOSD and MOGAD.

CNS drugs·2026
Same journal

Isoform-Specific NaV Modulation in Painful Chemotherapy-Induced Neuropathy: Promise, Limitations, and a Clinical Agenda.

CNS drugs·2026
Same journal

Correction: Seletracetam Revisited: A Missed Opportunity for Effective Epilepsy Therapy.

CNS drugs·2026
See all related articles

Area of Science:

  • Psychiatry
  • Pharmacology
  • Neuroscience

Background:

  • Schizophrenia is a chronic mental disorder characterized by positive, negative, and general symptoms.
  • Atypical antipsychotics offer improved efficacy and tolerability over older agents.
  • Perospirone is an atypical antipsychotic targeting serotonin 5-HT2A and dopamine D2 receptors.

Purpose of the Study:

  • To evaluate the efficacy and safety of perospirone in treating schizophrenia.
  • To compare perospirone's effectiveness against positive, negative, and general symptoms with established treatments.
  • To assess the onset of action and side effect profile of perospirone.

Main Methods:

  • Phase II and III clinical trials involving patients with schizophrenia.
  • Oral administration of perospirone (8-48 mg/day) for 8 weeks.

Related Experiment Videos

  • Comparative trials against haloperidol and mosapramine, using standard rating scales (e.g., BPRS, PANSS).

    • Main Results:

    • Perospirone demonstrated efficacy in up to 75% of patients, with a noticeable onset of action around 2 weeks.
    • Significant improvement in negative symptoms and trends for general and positive symptoms compared to haloperidol.
    • Similar efficacy to mosapramine, with a tendency for fewer and milder extrapyramidal symptoms (EPS).

    Conclusions:

    • Perospirone is an effective treatment for schizophrenia, addressing a broad spectrum of symptoms.
    • The drug exhibits a favorable safety profile, particularly regarding extrapyramidal side effects.
    • Perospirone represents a valuable therapeutic option for managing schizophrenia.